

#25

Patent
Attorney's Docket No. 002010-603

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

YEDNOCK et al.

Application No. 09/127,364

Filed: July 31, 1998

For: ANTI-INFLAMMATORY
COMPOSITIONS AND METHOD

Group Art Unit: 1653

Examiner: D. Lukton

Confirmation No.: 1040

RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In complete response to the Office Action of July 9, 2002, Applicants submit the following response. Please amend the application as follows.

In the Specification:

Please delete the paragraph at page 4, lines 8-13 of the originally-filed application and replace with the following:

—In preferred embodiments, pharmaceutical compositions and methods of treatment of the invention employ alpha-9 antagonist compounds that inhibit binding between alpha-9 integrin and an alpha-9 integrin ligand. Preferred ligands in this regard include any ligand found to specifically bind to alpha-9 integrin, as exemplified by osteopontin, tenascin, and VCAM-1. Due to its association with inflammatory reactions, VCAM-1 is particularly preferred for a test compound in this regard.—

Please delete the paragraph beginning at page 22, line 26 of the originally-filed application and replace with the following:

Adjustment date: 10/20/2003 AKELLEY
01/14/2003 CV0111 00000031 09127364
01 FC:1006 -750.00 0P

Received from < > at 9/22/03 3:11:39 PM [Eastern Daylight Time]

5/20/03 10/20/2003 AKELLEY 00000031 09127364
Ref: Date: Number: 0750
FC: 9204

RECEIVED

OCT 02 2003

OFFICE OF PETITIONS